Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vivesto AB ( (SE:VIVE) ) just unveiled an update.
Vivesto AB’s board has approved a directed issue of 31,050,000 new shares to guarantors of its recently completed rights issue, using the mandate granted at an extraordinary general meeting in December 2025. The compensation shares, priced at SEK 0.10 each and paid via set-off of guarantee commission claims, mainly reward existing shareholder Arwidsro Investment AB and certain other guarantors who opted for share-based compensation, while remaining guarantors will receive about SEK 2.6 million in cash. By settling most guarantee fees in shares rather than cash, Vivesto preserves liquidity and strengthens working capital, albeit at the cost of approximately 2.8 percent dilution for existing shareholders, with the total number of shares rising to 1,107,136,910; the board, advised by Bergs Securities, considers the terms market-based, underlining the company’s efforts to shore up its capital structure as it advances its oncology pipeline.
More about Vivesto AB
Vivesto AB is a Swedish drug development company focused on creating new treatments for hard-to-treat cancers with high medical need and strong market potential. Its pipeline includes Cantrixil for blood cancer and the veterinary oncology candidate Paccal Vet (paclitaxel micellar), currently being evaluated in clinical studies in dogs with splenic hemangiosarcoma and in cats with solid tumors. Vivesto is listed on Nasdaq Stockholm under the ticker VIVE.
Average Trading Volume: 1,574,166
Technical Sentiment Signal: Sell
Current Market Cap: SEK102.3M
For detailed information about VIVE stock, go to TipRanks’ Stock Analysis page.